NASDAQ: ALTAltimmune Inc Stock
$3.16+0.01 (+0.32%)
Updated Jul 2, 2026
ALT Price
$3.16
Fair Value Price
$0.09
Market Cap
$614.54M
52 Week Low
$2.56
52 Week High
$6.44
P/E
-3.43x
P/B
2.16x
P/S
10,620.69x
PEG
N/A
Dividend Yield
N/A
Revenue
$36.00k
Earnings
-$91.08M
Gross Margin
100%
Operating Margin
-245,494.44%
Profit Margin
-253,002.8%
Debt to Equity
0.18
Operating Cash Flow
-$72M
Beta
1.37
Next Earnings
Aug 11, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ALT Overview
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ALT's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ALT
Ranked#351 of 463
Ranked#351 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.29 | A | |
| $243.47 | A | |
| $15.61 | A |
Be the first to know about important ALT news, forecast changes, insider trades & much more!
ALT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ALT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALT ($3.16) is overvalued by 3,376.46% relative to our estimate of its Fair Value price of $0.09 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ALT ($3.16) is not significantly undervalued (3,376.46%) relative to our estimate of its Fair Value price of $0.09 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ALT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ALT due diligence checks available for Premium users.
Valuation
ALT fair value
Fair Value of ALT stock based on Discounted Cash Flow (DCF)
Price
$3.16
Fair Value
$0.09
Overvalued by
3,376.46%
ALT ($3.16) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ALT ($3.16) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ALT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ALT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.43x
Industry
17.59x
Market
8.54x
ALT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.16x
Industry
5.6x
ALT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ALT's financial health
Profit margin
Revenue
$0.0
Net Income
-$22.6M
Profit Margin
0%
ALT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ALT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$335.6M
Liabilities
$51.6M
Debt to equity
0.18
ALT's short-term assets ($334.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALT's short-term assets ($334.68M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ALT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$20.9M
Investing
-$3.7M
Financing
$78.5M
ALT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ALT vs Biotech Stocks
Altimmune Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.